Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Novartis

Main (CRISPR) focus: Treatment of genetic blood diseases and cancer

Company stage: Clinical

Diseases: Sickle cell disease, cancer

Genome editing tool: CRISPR-Cas9, Zinc-finger nuclease, Neuro-developmental disorders

Funding stage: Public (NASDAQ:NVS)

Location: Cambridge, MA, USA (Headquarters), Basel, Switzerland

Website: https://www.novartis.com/

Pipeline: https://www.novartis.com/our-science/novartis-global-pipeline

Partners: Intellia Therapeutics, Sangamo Therapeutics

Novartis is global big pharma company. The company is mainly involved in the therapeutic development of gene-editing technologies through a partnership with Intellia Therapeutics. The two companies are co-developing a programme for the treatment of sickle cell disease, which is currently being tested in early clinical trials. The companies are also developing multiple undisclosed pre-clinical assets.

Tags

HashtagNovartis AG

Company: Novartis
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine